Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869697 | 0.90 | ADORA1 (0.49) | ADORA1ADORA3ADORA2BADORA2ASLC6A3 | |
| SCHEMBL1866491 | 0.81 | ADORA1 (0.53) | ADORA1ADORA3ADORA2BADORA2ASLC6A3 | |
| SCHEMBL1897578 | 0.80 | ADORA1 (0.52) | ADORA1ADORA3ADORA2BADORA2ASLC6A3 | |
| SCHEMBL1873276 | 0.75 | ADORA1 (0.50) | ADORA1ADORA3ADORA2BADORA2ASLC6A3 | |
| SCHEMBL1897580 | 0.74 | ADORA1 (0.49) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL18059634 | 0.74 | ADORA1 (0.49) | ADORA1ADORA3ADORA2BADORA2ASLC6A3 | |
| SCHEMBL12092923 | 0.73 | ADORA1 (0.50) | ADORA1ADORA3ADORA2BADORA2ASLC6A3 | |
| SCHEMBL12089679 | 0.72 | ADORA1 (0.52) | ADORA1ADORA3ADORA2BADORA2ASLC6A3 | |
| SCHEMBL1868384 | 0.72 | ADORA1 (0.51) | ADORA1ADORA3ADORA2BADORA2ASLC6A3 | |
| SCHEMBL12081237 | 0.70 | ADORA1 (0.53) | ADORA1ADORA3ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499142-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2016-09-21 | — | — | EP | claimed |
| US-8796290-B2 | Substituted fused pyrimidine compounds, its preparation and uses thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-08-05 | — | — | US | claimed |
| US-20120225812-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-06 | — | — | US | claimed |
| EP-2499142-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2016-09-21 | — | — | EP | disclosed |
| US-8796290-B2 | Substituted fused pyrimidine compounds, its preparation and uses thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-08-05 | — | — | US | disclosed |
| EP-2499142-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | Advinus Therapeutics Limited (IN) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225812-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-06 | — | — | US | disclosed |
| WO-2011055391-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225812-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADORA1, ADORA2A, P2RY1 | ADORA1 1/4885ADORA3 4/4885ADORA2B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.